Search Results - "Cho–Phan, Cheryl"

Limitations of Body Surface Area–Based Activity Calculation for Radioembolization of Hepatic Metastases in Colorectal Cancer by Lam, Marnix G.E.H., MD, PhD, Louie, John D., MD, Abdelmaksoud, Mohamed H.K., MD, MS, Fisher, George A., MD, PhD, Cho-Phan, Cheryl D., MD, Sze, Daniel Y., MD, PhD

“…Abstract Purpose To calculate absorbed radiation doses in patients treated with resin microspheres prescribed by the body surface area (BSA) method and to…”
Get full text

Understanding Racial and Ethnic Inequities in Uptake and Outcomes Following Multigene Prognostic Testing in Early Breast Cancer: The Promise of Real-World Data by Wang, Xiaoliang, Cho-Phan, Cheryl D, Hoskins, Kent F, Calip, Gregory S

“…In the past decades, multigene prognostic testing, such as Oncotype DX (ODX), has been increasingly used to inform treatment decisions for patients with…”
Get full text

RAS Amplification as a Negative Predictor of Benefit from Anti‐EGFR–Containing Therapy Regimens in Metastatic Colorectal Cancer by Schrock, Alexa B., Lee, Jessica K., Sandhu, Jaideep, Madison, Russell, Cho‐Phan, Cheryl, Snider, Jeremy W., Castellanos, Emily, Venstrom, Jeffrey M., Fakih, Marwan

“…Background RAS short variant (SV) mutations in colorectal cancer (CRC) are associated with lack of benefit from epidermal growth factor receptor (EGFR)…”
Get full text

Increased Long-term Survival Among Patients With Hepatocellular Carcinoma After Implementation of Model for End-stage Liver Disease Score by Wong, Robert J, Devaki, Pardha, Nguyen, Long, Cheung, Ramsey, Cho–Phan, Cheryl, Nguyen, Mindie H

“…Background & Aims Assignment of Model for End-stage Liver Disease (MELD) exception points to patients with hepatocellular carcinoma (HCC) who fall within Milan…”
Get full text

ERBB2 copy number (CN) as a quantitative biomarker for real-world (RW) outcomes to anti-HER2 therapy in advanced gastroesophageal adenocarcinoma (adv GEA) by Klempner, Samuel J, Zhang, Liangliang, Graf, Ryon, Madison, Russell, Snider, Jeremy, Cho-Phan, Cheryl D., Castellanos, Emily, Li, Gerald, Nimeiri, Halla, Frampton, Garrett M., Oxnard, Geoffrey R., Venstrom, Jeffrey Michael, McGregor, Kimberly, Schrock, Alexa Betzig

“…Abstract only 4045 Background: HER2 ( ERBB2) overexpression or amplification (amp) are biomarkers for approved anti-HER2 therapies. ERBB2amp may be a superior…”
Get full text

Long-Term Survival of a Patient With Non–Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene by Myall, Nathaniel J, Neal, Joel W, Cho-Phan, Cheryl D, Zhou, Lisa Y, Stehr, Henning, Zhou, Li, Diehn, Maximilian, Wakelee, Heather A

Get full text

The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent by Scicinski, Jan, Fisher, George, Carter, Corey, Cho-Phan, Cheryl, Kunz, Pamela, Ning, Shoucheng, Knox, Susan, Oronsky, Bryan, Caroen, Scott, Parker, Christopher, Fanger, Gary, Reid, Tony

“…RRx-001 is a novel NO and hypoxia mediated anticancer agent with epigenetic activity. In the first-in-human, Phase I trial, 5/5 patients who progressed on…”
Get full text

Concordance of HER2+ status by IHC/ISH and ERBB2 status by NGS in a real-world clinicogenomic database and analysis of outcomes in patients (pts) with metastatic breast cancer (mBC) by Cho-Phan, Cheryl D., Snider, Jeremy, Zhang, Liangliang, McGregor, Kimberly, Schrock, Alexa Betzig, Castellanos, Emily

“…Abstract only 1036 Background: HER2 overexpression/amplification measured by IHC or ISH is a predictive biomarker for HER2-targeted therapies. Next-generation…”
Get full text

CtDNA shed as a tool to select immune checkpoint inhibitors (ICPI) with or without chemotherapy for patients (pts) with advanced non–small cell lung cancer (aNSCLC) by Besse, Benjamin, Madison, Russell, Cho-Phan, Cheryl D., Snider, Jeremy, Snow, Tamara, Dall'Olio, Filippo Gustavo, Tolba, Khaled A., Schrock, Alexa Betzig, Oxnard, Geoffrey R.

“…9045 Background: ICPI are compelling therapies for pts with aNSCLC given the potential for durable benefit and limited toxicity. Even in tumors with biomarkers…”
Get full text

Deriving real-world oral antineoplastic treatment endpoints: A comparison of automated data extraction versus manual chart abstraction by Chen, James Lin, Shadra, Chhaya, Cho-Phan, Cheryl D., Ghosh, Aradhana, Hirsch, Jonathan

“…Abstract only e18070 Background: Real world data (RWD) is increasingly being used to generate evidence that informs clinical care. Calculating outcomes…”
Get full text

An algorithmic approach to deriving line of therapy in a real-world data set for non-small cell lung cancer (NSCLC) by Shadra, Chhaya, Chen, James Lin, Cho-Phan, Cheryl D., Ghosh, Aradhana, Hirsch, Jonathan

“…Abstract only e18099 Background: Real World Data (RWD) is being used for outcomes research and regulatory submissions. A key variable needed to understand…”
Get full text

Abstract 864: Changes over time in real-world next-generation sequencing (NGS) test use in patients (pts) with advanced non-small cell lung cancer (aNSCLC) by Swaminathan, Akshay, Stergiopoulos, Stella, Snider, Jeremy, Fisher, Virginia, Castellanos, Emily, Snow, Tamara, Cho-Phan, Cheryl, Comment, Leah, Cunningham, Rachel, McCusker, Margaret E.

“…Background: Four-fold growth in the past decade of actionable molecular targets for aNSCLC makes comprehensive assessment of pts' alteration status…”
Get full text

Abstract CT086: Pneumonitis incidence in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy in clinical trials and real-world data by Liu, Qi, Zhang, Chenan, Gong, Yutao, Zhu, Hao, Chang, Elaine, Cho-Phan, Cheryl, Hirsch, Jonathan, Thompson, Michael A., Blumenthal, Gideon, Huang, Shiew Mei, Brown, Thomas D.

“…Background: Pneumonitis (Pn) is a potentially life-threatening adverse event of some anticancer drugs. We compared treatment associated pneumonitis (TAP)…”
Get full text

Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types by Gandara, David R., Agarwal, Neeraj, Gupta, Shilpa, Klempner, Samuel J, Andrews, Miles Cameron, Mahipal, Amit, Subbiah, Vivek, Eskander, Ramez Nassef, Carbone, David Paul, Snider, Jeremy, Bouzit, Lilia, Cho-Phan, Cheryl D., Price, Megan, Li, Gerald, Quintanilha, Julia C. F., Huang, Richard S.P., Ross, Jeffrey S., Fabrizio, David, Oxnard, Geoffrey R., Graf, Ryon

“…2503 Background: There is controversy around the applicability of TMB across cancer types and reliability between assays from different manufacturers. The…”
Get full text

Abstract 4257: Using Multilevel Regression and Poststratification (MRP) to inform estimates of biomarker prevalence for target populations of interest using linked clinico-genomic databases by Snider, Jeremy W., Beal, Brennan, Bouzit, Lilia, Cho-Phan, Cheryl, Comment, Leah, Frampton, Garrett, Snow, Tamara

“…Background Contemporary evidence on the size of biomarker-defined cancer populations is crucial for clinical and economic healthcare decision makers. Estimates…”
Get full text

Real-world overall survival (OS) and time to therapy discontinuation (TTD) of patients (pts) with mCRPC treated with second-generation novel hormonal therapies (NHT) associated with tissue-based comprehensive genomic profiling (CGP) by Graf, Ryon, Madison, Russell, Gjoerup, Ole, Zhong, Lei, Morley, Samantha, Chopra, Sunandini, Comment, Leah, Fisher, Virginia, Li, Gerald, McGregor, Kimberly, Schrock, Alexa Betzig, Tukachinsky, Hanna, Snow, Tamara, Cho-Phan, Cheryl D., Swaminathan, Akshay, Ross, Jeffrey S., McCusker, Margaret Elizabeth, Zurita, Amado J., Venstrom, Jeffrey

“…Abstract only 142 Background: Robust biomarkers for personalization of NHT treatment decisions remains an unmet need. Most assessments of candidate biomarkers…”
Get full text

ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti-Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma by Zhang, Liangliang, Hamdani, Omar, Gjoerup, Ole, Cho-Phan, Cheryl, Snider, Jeremy, Castellanos, Emily, Nimeiri, Halla, Frampton, Garrett, Venstrom, Jeffrey M, Oxnard, Geoffrey, Klempner, Samuel J, Schrock, Alexa B

“…Human epidermal growth factor receptor 2 (HER2) overexpression or amplification ( amp) are biomarkers for approved anti-HER2 therapies. amp may better predict…”
Get more information

Abstract B26: RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing phase 2 colorectal cancer study, ROCKET by Reid, Tony, Fisher, George, Carter, Corey, Cho-Phan, Cheryl, Kunz, Pamela, Oronsky, Bryan, Fanger, Gary, Stirn, Meaghan, Caroen, Scott, Parker, Christopher, Scicinski, Jan

“…Background: The development of resistance to chemotherapies in cancer leads to disease progression resulting in impaired survival. Resensitization to these…”
Get full text

Abstract CT119: Early results from a phase II study of RRx-001, a novel, triple epigenetic inhibitor, showing resensitization to irinotecan in colorectal cancer by Reid, Tony, Fisher, George, Carter, Corey, Cho-Phan, Cheryl, Kunz, Pamela, Oronsky, Bryan, Fanger, Gary R., Caroen, Scott, Parker, Christopher, Scicinski, Jan

“…Background: Resistance acquisition to standard therapy in advanced colon cancer leads to poor patient survival. Epigenetic therapies can potentially reverse…”
Get full text

Abstract A1-35: RRx-001, a novel first in class epigenetic modulator, “episensitizes” colorectal patients to FOLFIRI: Preliminary resensitization data from the Phase 2 “ROCKET” study by Reid, Tony, Carney, Jennifer, Beale, Keola, Clayton, Chan, Nguyen, Huy, Cho-Phan, Cheryl, Stirn, Meaghan, Ning, Shoucheng, Knox, Susan, Oronsky, Bryan, Scicinski, Jan, Caroen, Scott, Parker, Christopher, Fanger, Gary R., Fisher, George

“…Background: RRx-001 is a novel systemically non-toxic pan-epigenetic modulator of DNA methyltransferases, Histone Deacetylases, and lysine demethylases with…”
Get full text